CytomX appoints Rachel Humphrey to board
This article was originally published in Scrip
Executive Summary
CytomX, a biotechnology company developing therapeutics for the treatment of cancer, has named Dr Rachel Humphrey to its board of directors. Dr Humphrey previously led immuno-oncology at AstraZeneca and prior to that was responsible for the clinical development of both Yervoy (ipilimumab) at Bristol-Myers Squibb and Nexavar (sorafenib) at Bayer.